Vyleesi (Bremelanotide) Monitoring in Older Adults Aged 50 to 64

Why Older Adults Need a Different Monitoring Plan

Women between 50 and 64 occupy a clinical gray zone for bremelanotide. The drug carries FDA approval specifically for premenopausal women with acquired, generalized HSDD, yet many patients in their early 50s remain premenopausal or perimenopausal and meet diagnostic criteria. Their baseline cardiovascular risk, medication burden, and hormonal variability all exceed what the key trial population reflected.

In the RECONNECT phase 3 trial (N=1,247), bremelanotide 1.75 mg produced statistically significant improvements in sexual desire and distress scores compared with placebo over 24 weeks [1]. The trial enrolled premenopausal women aged 18 and older. Subgroup data showed consistent efficacy across age brackets, but the median age of participants skewed toward the 30s and 40s. Fewer than 15% of enrolled women were over 50 [1]. That data gap means clinicians prescribing to women in their 50s and early 60s must build a monitoring framework around the drug's known pharmacology and the patient's individual risk profile rather than relying on strong trial data from this specific cohort.

The FDA label warns that bremelanotide causes transient increases in systolic blood pressure (average 6 mmHg) and diastolic blood pressure (average 3 mmHg), with peak effects occurring within 2 to 3 hours post-dose and resolving within 12 hours [2]. For a 35-year-old with normal blood pressure, that transient rise is clinically negligible. For a 58-year-old with stage 1 hypertension on amlodipine, it could push readings into a range associated with increased stroke and cardiac event risk, particularly if she also takes a nasal decongestant or NSAID that day.

Blood Pressure Monitoring Protocol

Home blood pressure tracking is the cornerstone of safe bremelanotide use in this age group. Every patient aged 50 to 64 should own a validated upper-arm cuff and log readings at three time points on dosing days: (1) immediately before injection, (2) two hours post-dose, and (3) the following morning.

The American Heart Association defines normal blood pressure as below 120/80 mmHg and elevated blood pressure as 120 to 129 systolic with diastolic below 80 mmHg [3]. Stage 1 hypertension begins at 130/80 mmHg. For women already in the elevated or stage 1 range, a transient 6/3 mmHg increase from bremelanotide could push systolic readings above 140 mmHg, the threshold historically associated with accelerated end-organ damage in longitudinal studies [3].

A practical monitoring protocol for the first month of bremelanotide use includes these steps. Obtain a baseline in-office blood pressure average from three readings taken on separate days before the first prescription. Confirm the patient can demonstrate correct home cuff technique. Have the patient log all three time-point readings for the first four dosing occasions and bring those logs to a follow-up visit. If any post-dose systolic reading exceeds 160 mmHg or any diastolic exceeds 100 mmHg, the patient should contact her prescriber before the next dose.

After the first month, patients with consistently normal post-dose readings can reduce logging frequency to once monthly. Patients on antihypertensive medications should continue the full three-point log indefinitely.

Cardiovascular Risk Screening Before the First Dose

A resting 12-lead ECG is not universally required by the bremelanotide label, but the American College of Cardiology and AHA 2019 guidelines on primary prevention recommend cardiovascular risk assessment for all adults, with particular attention to women over 50 who have entered or are approaching menopause [4]. Estrogen decline during perimenopause accelerates atherosclerotic plaque formation and endothelial dysfunction [5]. Adding a drug that transiently raises blood pressure and can cause flushing (reported in 20% of RECONNECT participants) warrants a screening conversation at minimum [1].

Before prescribing bremelanotide to a woman aged 50 to 64, clinicians should calculate her 10-year atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations. A score above 7.5% warrants deeper evaluation. A fasting lipid panel, fasting glucose or HbA1c, and a resting ECG form a reasonable baseline workup for moderate-risk patients. High-risk patients (10-year ASCVD score above 20%, established coronary artery disease, or prior stroke) represent a population where the risk-benefit calculus of bremelanotide requires careful individualized discussion. The FDA label does not list cardiovascular disease as an absolute contraindication, but it does note that the drug has not been studied in patients with uncontrolled hypertension or recent cardiovascular events [2].

Dr. Sheryl Kingsberg, a lead investigator on the RECONNECT trial, has stated: "Clinicians should approach HSDD treatment in older premenopausal women with the same cardiovascular diligence they would apply to any new pharmacotherapy in a patient with evolving risk factors" [1].

Polypharmacy Review and Drug Interactions

Women aged 50 to 64 take a median of four prescription medications, according to CDC National Health and Nutrition Examination Survey data [6]. That medication burden creates interaction potential that younger bremelanotide users rarely face.

Bremelanotide is a melanocortin-4 receptor agonist. It slows GI motility, which the FDA label flags as a reason to avoid co-administration with oral medications that depend on a specific absorption threshold [2]. Patients taking oral naltrexone for alcohol use disorder, for instance, may experience reduced naltrexone absorption. The label specifically contraindicates concurrent use with naltrexone, whether oral or injectable [2].

Beyond the naltrexone contraindication, several common medication classes in this age group require attention. Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers) combine with bremelanotide's pressor effect in unpredictable ways. Some patients experience blunting of the blood pressure spike; others experience additive hypertension. That variability is why home monitoring is non-negotiable.

SSRIs and SNRIs deserve special mention. Many women aged 50 to 64 take these for depression, anxiety, or vasomotor symptoms. SSRIs are themselves a recognized cause of decreased libido, and a 2018 systematic review in the Journal of Clinical Psychiatry found that SSRI-induced sexual dysfunction affects 40% to 65% of patients across age groups [7]. If a patient's HSDD is partially or entirely driven by SSRI use, bremelanotide may provide symptom relief, but it does not address the pharmacologic root cause. The monitoring plan should include a conversation about whether SSRI dose reduction, switching, or augmentation with bupropion might be more appropriate than adding bremelanotide.

Hormone therapy (estrogen, progesterone, testosterone) is common in perimenopausal women. Bremelanotide was not studied in combination with systemic hormone therapy in the RECONNECT trial [1]. There are no known direct pharmacokinetic interactions, but the clinical picture becomes harder to interpret when multiple agents affect libido, mood, and cardiovascular parameters simultaneously. Document the patient's complete hormone regimen at baseline and note any changes at each monitoring visit.

Menopausal Status Reassessment

This monitoring element is unique to older adults. Bremelanotide's FDA-approved indication is limited to premenopausal women [2]. A 52-year-old patient who was clearly premenopausal at the time of her first prescription may transition to postmenopausal status within 6 to 12 months. The North American Menopause Society defines menopause as 12 consecutive months of amenorrhea in the absence of other biological or physiological causes [8].

Reassess menopausal status at every follow-up visit. Ask about menstrual regularity, vasomotor symptoms, and vaginal dryness. If a patient reports 6 or more months of amenorrhea, check serum FSH and estradiol levels. An FSH level persistently above 30 mIU/mL with estradiol below 20 pg/mL is consistent with menopause [8]. Once a patient meets postmenopausal criteria, continued bremelanotide prescribing moves into off-label territory. That does not mean the drug must be stopped, but it does mean the prescriber should document the clinical rationale, confirm ongoing efficacy, and discuss the off-label status with the patient.

The distinction matters for insurance coverage as well. Many payers authorize bremelanotide only for patients who meet the FDA-labeled population. A patient who becomes postmenopausal may face coverage denial at her next refill.

Nausea Management and GI Monitoring

Nausea is the most common adverse event with bremelanotide. The RECONNECT trial reported nausea in 40.0% of bremelanotide-treated women versus 1.3% on placebo [1]. The nausea is dose-related, typically peaks 1 to 2 hours post-injection, and diminishes with repeated dosing over the first few uses.

For older adults, nausea management intersects with two practical concerns. First, many women aged 50 to 64 already take medications that cause GI distress (metformin, bisphosphonates, iron supplements, NSAIDs). Adding bremelanotide-induced nausea on top of existing GI sensitivity can reduce adherence rapidly. Second, some patients in this age group take antiemetics such as ondansetron or promethazine for other conditions. Promethazine has anticholinergic properties that can worsen constipation already slowed by bremelanotide's effects on GI motility.

Practical steps include timing bremelanotide on an empty stomach or 2 hours after a light meal (small studies suggest food does not significantly alter absorption but may worsen nausea), keeping the injection site on the abdomen where absorption is most consistent, and pre-treating with ginger or low-dose ondansetron if nausea was severe on the first two dosing attempts. If nausea persists beyond the fourth use, reassess whether the clinical benefit justifies continued therapy.

Skin Hyperpigmentation Surveillance

Bremelanotide activates melanocortin-1 receptors in addition to its primary MC4R target. That off-target activity can cause focal skin darkening, particularly at injection sites and on the gums, face, and breasts [2]. In the RECONNECT trial, hyperpigmentation occurred in approximately 1% of bremelanotide-treated participants, and it did not fully resolve in all cases after discontinuation [1].

For older adults, the monitoring concern is twofold. Age-related lentigines and melanocytic changes already increase in frequency after age 50. New or changing pigmented lesions require differentiation from melanoma. Document baseline mole maps or photograph existing pigmented lesions before initiating bremelanotide. At each follow-up, inspect injection sites and the oral mucosa. Any new pigmented lesion, or a change in size, border, or color of an existing one, warrants dermatologic referral before attributing it to the drug.

Follow-Up Schedule and Documentation

A structured monitoring timeline reduces both clinical risk and medicolegal exposure. The suggested cadence for women aged 50 to 64 starting bremelanotide follows this pattern.

Pre-prescription visit: Confirm premenopausal status, calculate ASCVD risk score, obtain baseline labs (lipid panel, fasting glucose, FSH/estradiol if any menstrual irregularity), review full medication list for interactions, and record baseline blood pressure from three separate readings.

Two-week phone or telehealth check: Review home blood pressure logs from the first two to four dosing occasions. Assess nausea severity and adherence. Confirm no syncopal or pre-syncopal episodes.

Six-week in-office visit: Repeat blood pressure in office. Review efficacy using a validated patient-reported outcome such as the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale-Revised (FSDS-R). Inspect injection sites for hyperpigmentation. Confirm medication list is unchanged.

Three-month visit: Full reassessment. Repeat FSH/estradiol if the patient reported menstrual changes. Review blood pressure log trends. Decide whether to continue, adjust monitoring frequency, or discontinue.

Every six months thereafter: Menopausal status check, blood pressure trend review, dermatologic inspection, polypharmacy update, and efficacy reassessment.

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women notes that any pharmacotherapy for female sexual dysfunction should be reassessed for ongoing benefit at 3 to 6 month intervals [9]. That recommendation, while written for testosterone, applies logically to bremelanotide. A drug that is not producing measurable benefit should not be continued simply because it was started.

When to Discontinue or Refer

Stop bremelanotide and refer to cardiology if a patient develops sustained post-dose systolic blood pressure above 180 mmHg, new-onset chest pain, or palpitations lasting more than 30 minutes. Stop and refer to dermatology if new pigmented lesions appear that cannot be confidently attributed to the drug. Stop and reassess the HSDD diagnosis if the patient transitions to confirmed postmenopausal status and wishes to continue treatment, as the underlying hormonal milieu has changed and alternative therapies (vaginal estrogen, systemic hormone therapy, psychosexual counseling) may now be more appropriate.

A 2021 review in the Journal of Women's Health emphasized that HSDD in women over 50 is often multifactorial, involving declining estrogen, relationship changes, comorbid depression, and medication side effects [10]. Bremelanotide addresses one pathway. Monitoring should always include a broader clinical lens.

The minimum post-dose blood pressure reading that should trigger a same-day clinical contact is 160/100 mmHg sustained at both the 2-hour and next-morning measurements.